Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Aisyah Noor
MS
Aisyah Noor
Morgan Stanley
Wall Street Analyst
Not yet ranked — too few measurable calls.
50%
Success Rate
+11.5%
Average Return
1 of 2 calls profitable · +6.9% vs benchmark
📈 Across the calls we could measure, roughly 50% of Aisyah Noor's ratings turned a profit when each position was held for 1 year — averaging +11.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

20 Buy 36 Hold 16 Sell
Aisyah's Stock Coverage 18 ratings · 2026-07-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CH:STMN
Straumann Holding AG
 Jun 30, 2026 SELL Buy
+17.7% avg upside
15 analysts
$85.00
18.68% Downside
 ·
FR:BIM
bioMerieux
 Jun 23, 2026 SELL Buy
+40.6% avg upside
12 analysts
$64.00
8.21% Downside
 ·
QGEN
Qiagen
 Jun 23, 2026 BUY Buy
+0.5% avg upside
24 analysts
$42.00
1.26% Upside
 ·
DE:FRE
Fresenius SE & Co. KGaA
 Jun 23, 2026 BUY Strong Buy
+22.4% avg upside
20 analysts
$48.00
16.26% Upside
 ·
NL:PHIA
Koninklijke Philips N.V.
 Jun 23, 2026 HOLD Buy
+29.2% avg upside
21 analysts
$25.00
5.20% Upside
 ·
GB:SN
Smith & Nephew
 Jun 23, 2026 BUY Strong Buy
+1203.6% avg upside
16 analysts
$1333.00
16.00% Upside
 ·
CH:SOON
Sonova Holding AG
 Jun 23, 2026 HOLD Sell
+8.8% avg upside
17 analysts
$205.00
0.81% Upside
 ·
DE:SHL
Siemens Healthineers AG
 Jun 23, 2026 HOLD Strong Buy
+41.5% avg upside
24 analysts
$37.00
5.35% Upside
 ·
CH:TECN
Tecan Group AG
 Jun 23, 2026 HOLD Buy
+80.7% avg upside
8 analysts
$142.00
21.32% Downside
 ·
WILLF
Demant
 Jun 23, 2026 BUY Strong Buy
-4.1% avg upside
19 analysts
$44.21
6.56% Upside
 ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 May 06, 2026 SELL Buy
+19.7% avg upside
22 analysts
$33.00
22.60% Downside
 ·
GB:CTEC
ConvaTec
 Apr 09, 2026 BUY Strong Buy
+36.7% avg upside
17 analysts
$270.00
27.59% Upside
 ·
IT:DIA
DiaSorin S.p.A.
 Mar 23, 2026 HOLD Hold
+56.0% avg upside
10 analysts
$60.00
12.98% Downside
 ·
GB:0QBO
Coloplast A/S
 Dec 15, 2025 SELL Buy
+80.5% avg upside
17 analysts
$541.00
34.41% Upside
 ·
CH:MOVE
Medacta Group SA
 Sep 09, 2025 BUY Buy
+5.2% avg upside
4 analysts
$161.00
15.23% Upside
 ·
SE:GETI.B
Getinge
 Jul 23, 2025 HOLD Hold
+5.7% avg upside
7 analysts
$175.00
16.31% Downside
 ·
CH:DOCM
DocMorris
 Mar 18, 2025 HOLD Hold
-10.0% avg upside
8 analysts
$20.00
95.42% Upside
 ·
DE:RDC
Redcare Pharmacy
 Mar 12, 2025 HOLD Strong Buy
+39.9% avg upside
7 analysts
$147.00
123.97% Upside
 ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Aisyah Noor — Frequently Asked Questions
How accurate are Aisyah Noor's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Aisyah's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, or +6.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Aisyah ranked on 13Foresight?
Aisyah Noor is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Aisyah cover?
Aisyah most recently has ratings on CH:STMN, FR:BIM, QGEN, DE:FRE, NL:PHIA, GB:SN, CH:SOON, DE:SHL, CH:TECN, WILLF, DE:FME, GB:CTEC and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.